-62%

est. 2Y upside i

HealthcareAI & MLSeed

Nearly every disease will become treatable in our lifetimes. Mandolin is laying the clinical and financial infrastructure to get groundbreaking treatments to patients faster, powered by AI agents. Mandolin partners closely with the largest healthcare institutions in the US, covering more than $10B drug spend across the country.

Rank

#381

Sector

HealthTech, AI Automation

Est. Liquidity

~4Y

Data Quality

Data: Low

Mandolin presents a strong upside opportunity for a job seeker, driven by its innovative AI automation platform addressing a critical and rapidly growing specialty drug market (projected $1.5T by mid-2030s).

Last updated: March 10, 2026

Bull (35%)+300%

Mandolin rapidly expands its AI agent platform, becoming the dominant player in specialty drug access automation. Deep integrations and superior AI performance lead to significant market share gains from legacy systems, pushing valuation to $800M (4x current) as the company achieves a Series C or D round, demonstrating strong revenue growth and clear path to profitability.

Base (40%)+100%

Mandolin continues to execute on its current trajectory, securing a strong position in the specialty drug access market. It achieves steady customer growth and product enhancements, leading to a successful Series B or C round at a $400M valuation (2x current) within the next 2-3 years, driven by consistent revenue expansion and continued investor confidence.

Bear (25%)-80%

Incumbent EHR vendors or large RCM players (e.g., Waystar, Innovaccer) launch more competitive AI-driven solutions, or regulatory changes create unforeseen challenges. Mandolin struggles to maintain its growth rate and market differentiation, leading to a down round or a modest acquisition at a $40M valuation, significantly eroding common stock value due to liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Investors hold $40M in liquidation preferences. In an exit at or below $40M, common shareholders would receive nothing. In a $100M exit, common shareholders would receive $60M after preferred shares are paid out.

Dilution Risk

high

As a Series A company, Mandolin will likely raise additional funding rounds, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

Early-stage companies like Mandolin typically do not have active secondary markets for employee equity.

Operations — 3 roles

Product — 2 roles

Marketing — 1 role

View all 11 open roles at Mandolin →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Mandolin's data — designed to show you've done your homework.

  • 1

    “Mandolin has achieved rapid adoption in over 700 clinic locations since January 2025. How do you plan to scale this growth while maintaining the deep integrations and specialized service that form your competitive moat, especially against broader RCM players like Waystar?”

  • 2

    “The specialty drug market is projected to reach $1.5 trillion by the mid-2030s. What are Mandolin's key strategic priorities over the next 2-3 years to capture a significant share of this growing market, particularly considering the 'medium' incumbent threat from large EHR vendors and established RCM companies?”

  • 3

    “Given the $40M Series A funding and the current $200M valuation, how does Mandolin envision the path to a liquidity event for employees, and what are the company's plans regarding future funding rounds and potential secondary liquidity options within a 2-5 year timeframe?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.